Market Place
Sourcing Support
Neurana Pharmaceuticals Seeks Strategic Alternatives Following Phase 3 Study
22 Mar 2022 //
PRNEWSWIRE
Neurana concludes subject enrolment in trial of muscle spasm therapy
30 Nov 2021 //
CLINICALTRIALSARENA
Neurana Pharmaceuticals Completes Patient Enrollment in Phase 3 RESUME-1 Study
29 Nov 2021 //
PRNEWSWIRE
Neurana Pharmaceuticals to Present at Wells Fargo Virtual Healthcare Conference
02 Sep 2021 //
PRNEWSWIRE
Neurana Pharmaceuticals to Present at Napa Pain Conference and PAIN Week
30 Aug 2021 //
PRNEWSWIRE
Neurana Pharmaceuticals to Participate at the SVB Leerink Conference
19 Jul 2021 //
PR NEWSWIRE
Neurana Pharmaceuticals to Participate at William Blair Biotech Conference
12 Jul 2021 //
PRNEWSWIRE
Neurana Pharmaceuticals Announces 50% Enrollment in Phase 3, RESUME-1 Study
07 Jun 2021 //
PRNEWSWIRE
Neurana to Present at Piper Sandler 32nd Annual Healthcare Conference
24 Nov 2020 //
PRNEWSWIRE
Neurana Pharmaceuticals Announces Publication in the Journal of Pain Research
23 Nov 2020 //
BIOSPACE
Neurana Pharmaceuticals to Present Tolperisone Data at PAINWeek®
02 Sep 2020 //
PRNNEWSWIRE
Neurana Announces First Patient Enrolled in CNS Effects Clinical Study
08 Jun 2020 //
PRNEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.